For researchers submitting trial data to ClinicalTrials.gov, the Adverse Events module is one of four mandatory results sections. It requires reporting in three primary categories: All-Cause Mortality: A table tracking all deaths that occurred during the study, regardless of cause. Serious Adverse Events (SAEs): A tabular summary of events resulting in death, life-threatening conditions, hospitalization, or significant disability. Other Adverse Events: A table for non-serious events that exceed a specific frequency threshold, such as 5% within any study arm.
Adverse Events Module path is as follows:
Study -> Results Section -> Adverse Events Module -> Event Groups
Study -> Results Section -> Adverse Events Module -> Serious Events
Study -> Results Section -> Adverse Events Module -> Other Events
| Title | Description | Deaths # Affected | Deaths # At Risk | Serious # Affected | Serious # At Risk | Other # Affected | Other # At Risk | View |
|---|---|---|---|---|---|---|---|---|
| Sirolimus Treatment | Sirolimus treatment sirolimus: Tablet or liquid; taken once or twice daily; dosage is based on establishing a serum trough of 5-15 ng/ml by high-performance liquid chromatography (initial loading dose of 3 mg/m2 then 2.5 mg/m2 with adjustment based on serum trough) | None | None | 1 | 30 | 15 | 30 | View |
| Term | Type | Organ System | Vocab | View |
|---|---|---|---|---|
| Vasculitis | SYSTEMATIC_ASSESSMENT | Nervous system disorders | None | View |
| Term | Type | Organ System | Vocab | View |
|---|---|---|---|---|
| Mucositis | SYSTEMATIC_ASSESSMENT | Gastrointestinal disorders | None | View |
| Elevated triglycerides and cholesterol | SYSTEMATIC_ASSESSMENT | Cardiac disorders | None | View |
| Acne | SYSTEMATIC_ASSESSMENT | Skin and subcutaneous tissue disorders | None | View |
| Sun sensitivity | SYSTEMATIC_ASSESSMENT | Skin and subcutaneous tissue disorders | None | View |
| Gastro-esophageal reflux disease | SYSTEMATIC_ASSESSMENT | Gastrointestinal disorders | None | View |